TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10638351

Group type: EXPERIMENTAL
Intervention: EEG biofeedback treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age matched reference normative QEEG database
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double blind research study
Number of subjects: 0
Study: 8929256

Group type: EXPERIMENTAL
Intervention: pravastatin 40 mg o.d.
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg b.i.d.
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: gemfibrozil + pravastatin (same doses)
Number of subjects: 147

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 147
Study: 1404679

Group type: EXPERIMENTAL
Intervention: 650 mg aspirin twice daily
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin or low-dose aspirin (80 to 325 mg daily)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Regular aspirin
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Overall aspirin usage
Number of subjects: 444
Study: 3981950

Group type: EXPERIMENTAL
Intervention: Low molecular-weight heparin (LMW heparin) at 50% of the normal unfractionated heparin (UF heparin) dose
Number of subjects: 49

Group type: COMPARATOR
Intervention: Unfractionated heparin (UF heparin)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Low molecular-weight heparin (LMW heparin)
Number of subjects: 49

Group type: COMPARATOR
Intervention: UF heparin and LMW heparin
Number of subjects: 49
Study: 3286383

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 11.1 mg/kg per day (group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ursomenth (UDCA/menthol mixture: 4.75 mg/kg per day each) (group B)
Number of subjects: 33
Study: 30916194

Group type: EXPERIMENTAL
Intervention: β1 specific beta-blockers + alpha 1-blocker
Number of subjects: 18

Group type: COMPARATOR
Intervention: β1 non-specific beta-blockers
Number of subjects: 18
Study: 27618578

Group type: EXPERIMENTAL
Intervention: Immediate intervention group (n=7)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Delayed-intervention, waiting list control group (n=14)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Pooled intervention data (n=21)
Number of subjects: 27
Study: 25168020

Group type: EXPERIMENTAL
Intervention: 2-MP-General LCD monitor
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2-MP-Medical LCD monitor
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3-MP-Medical LCD monitor
Number of subjects: 100
Study: 23499394

Group type: EXPERIMENTAL
Intervention: Foot bath containing green tea polyphenols (GTP)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo treatment (lukewarm water foot bath)
Number of subjects: 94
Study: 21545249

Group type: EXPERIMENTAL
Intervention: Inhaled montelukast 1 mg plus inhaled mometasone 220 μg
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo plus inhaled mometasone 220 μg
Number of subjects: 134
Study: 19789401

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of bone marrow-derived mononuclear cells (BMC) within 7 days after successful reperfusion therapy for AMI.
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 187
Study: 16730616

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/d for 12 weeks
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/d for 12 weeks with aggressive toenail debridement
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 15127196

Group type: EXPERIMENTAL
Intervention: Clinical pulmonary infection score (CPIS) > 6 on day 3
Number of subjects: 201

Group type: COMPARATOR
Intervention: Bronchoscopy-based diagnosis of VAP
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: CPIS > 6 on day 3
Number of subjects: 201
Study: 11116283

Group type: EXPERIMENTAL
Intervention: Fedotozine
Number of subjects: 0
Study: 9565786

Group type: EXPERIMENTAL
Intervention: Flash lamp‐pumped pulsed dye laser (FPDL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 40
Study: 7840428

Group type: EXPERIMENTAL
Intervention: Teflon FEP catheter (Cathlon Critikon)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Polyurethane Vialon catheter (Insyte Becton‐Dickinson)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Stainless steel needles
Number of subjects: 350
Study: 2826526

Group type: COMPARATOR
Intervention: Insulin (0.1 U/kg, iv) followed by placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin (0.1 U/kg, iv) followed by oral clonidine (0.150 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral clonidine (0.150 mg) followed by iv placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral clonidine (0.150 mg) followed by iv insulin (0.1 U/kg)
Number of subjects: 16
Study: 30899972

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (tidal volume 7ml/kg ideal body weight, PEEP ideal body weight/10), n=535
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Apnea (manual/spontaneous, APL valve 0mbar), n=486
Number of subjects: 1021
Study: 28422533

Group type: COMPARATOR
Intervention: Traditional Resistance Training (TD)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Pyramid Resistance Training (PR)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Control Group (CG)
Number of subjects: 59
Study: 26602298

Group type: EXPERIMENTAL
Intervention: Infant feeding intervention delivered by 9 village health workers
Number of subjects: 19
Study: 24325771

Group type: EXPERIMENTAL
Intervention: Health education counseling
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Smoking cessation (regardless of counseling type)
Number of subjects: 755
Study: 22111770

Group type: EXPERIMENTAL
Intervention: Daily supplementation with multiple micronutrient powder (MMP) for 24 weeks (n = 111)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Twice weekly supplementation with multiple micronutrient powder (MMP) for 24 weeks (n = 115)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group (n = 110)
Number of subjects: 336
Study: 19271165

Group type: EXPERIMENTAL
Intervention: Xinyue Capsule (XYC) plus Composite Salvia Tablet (CST)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 16971855

Group type: EXPERIMENTAL
Intervention: 4% human albumin
Number of subjects: 691

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: 4% human albumin with >3 L of fluids in the first 24 hrs
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation (amount)
Number of subjects: 691
Study: 15563344

Group type: EXPERIMENTAL
Intervention: Caffeine (1.75 mg/kg) three times daily for 4 consecutive weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sleep restriction
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cognitive activity
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 11251924

Group type: EXPERIMENTAL
Intervention: Saline contrast sonohysterography (SCSH)
Number of subjects: 233
Study: 9394856

Group type: EXPERIMENTAL
Intervention: Anastrozole, 1 mg once daily, orally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formestane, 250 mg every 2 weeks, intramuscularly
Number of subjects: 0
Study: 7896425

Group type: EXPERIMENTAL
Intervention: Cuprophan (CU) dialyzer
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Hemophane (HE) dialyzer
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Polyamide (PA) dialyzer
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: High blood-flow (Qb)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Low blood-flow (Qb)
Number of subjects: 234
Study: 2446082

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 30040023

Group type: EXPERIMENTAL
Intervention: Smartphone inclinometer application on iPhone 6 (IP)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Smartphone inclinometer application on Android (AN)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison of average peak and total UCROM between devices
Number of subjects: 38
Study: 28931197

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 0.4 mg/kg/day for 4 weeks, tapered to 0.2 mg/kg/day for 2 months, and to 0.1 mg/kg/day for the last 2 months (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral prednisolone tapered within 2 months (Group B)
Number of subjects: 60
Study: 25348255

Group type: EXPERIMENTAL
Intervention: LY500307 1 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: LY500307 3 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: LY500307 10 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: LY500307 25 mg
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study: 23989256

Group type: EXPERIMENTAL
Intervention: Minodronate (1.0 mg daily)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Risedronate (daily treatment combined with 1000 IU ergocalciferol and 1200 mg elemental calcium)
Number of subjects: 256
Study: 21341397

Group type: COMPARATOR
Intervention: S-equol (10-320 mg single dose)
Number of subjects: 101

Group type: COMPARATOR
Intervention: S-equol (10-160 mg, BID for 14 days)
Number of subjects: 101

Group type: COMPARATOR
Intervention: S-equol (20 mg single dose with food)
Number of subjects: 101

Group type: COMPARATOR
Intervention: S-equol (various doses)
Number of subjects: 101

Group type: COMPARATOR
Intervention: S-equol (320 mg single dose)
Number of subjects: 101
Study: 19489805

Group type: EXPERIMENTAL
Intervention: Individual educational intervention about infant sleep position (supine position)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 228
Study: 17893573

Group type: EXPERIMENTAL
Intervention: propofol‐remifentanil (T group; n=80 patients)
Number of subjects: 162

Group type: COMPARATOR
Intervention: sevoflurane‐fentanyl (S group; n=82 patients)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study: 15310633

Group type: EXPERIMENTAL
Intervention: Tandospirone 10 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clonidine 3 microg.kg(‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 11402752

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 0
Study: 8995995

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (5 mg) - single dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (5 mg) - double dose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8355469

Group type: EXPERIMENTAL
Intervention: Fish oil (15 g/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 26
Study: 3117876

Group type: EXPERIMENTAL
Intervention: Clomipramine (150 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg)
Number of subjects: 50
Study: 29906273

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D concentrations ≥60 ng/ml
Number of subjects: 5038

Group type: COMPARATOR
Intervention: 25-hydroxyvitamin D concentrations <20 ng/ml
Number of subjects: 5038
Study: 28868878

Group type: EXPERIMENTAL
Intervention: Spleen, liver and kidney-strengthening formula combined with polyethylene glycol interferon α‐2a (or α‐2b)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Polyethylene glycol interferon α‐2a (or α‐2b)
Number of subjects: 126
Study: 24814304

Group type: EXPERIMENTAL
Intervention: Recall with EM (eye movements)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Recall only (without eye movements)
Number of subjects: 73
Study: 22777878

Group type: EXPERIMENTAL
Intervention: SWEEP
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 74
Study: 19664300

Group type: EXPERIMENTAL
Intervention: High-wheat fibre cereal (24 g fibre/d)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-fibre cereal (control)
Number of subjects: 14
Study: 18401223

Group type: EXPERIMENTAL
Intervention: Pharmacist recommendations to physicians in intervention clinics
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard care in control clinics
Number of subjects: 179
Study: 16494210

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intermediate flora (Group II)
Number of subjects: 120
Study: 12197862

Group type: EXPERIMENTAL
Intervention: Behavioural therapy (coping skills training and cognitive therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-specific supportive therapy
Number of subjects: 120
Study: 11563413

Group type: EXPERIMENTAL
Intervention: Rizatriptan (1 mg) with Paroxetine (20 mg once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rizatriptan (1 mg)
Number of subjects: 12
Study: 7554037

Group type: EXPERIMENTAL
Intervention: CPT-11 AUC (ng h ml-1) using a trivariate model: CPT‐11 AUC = 0.820 x C0.5h + 0.402 x C1h + 15.47 x C6h + 928
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: SN-38 AUC (ng h ml-1) using a trivariate model: SN‐38 AUC = 4.05 x C0.5h ‐0.81 x C1h + 23.01 x C6h ‐ 69.78
Number of subjects: 64
Study: 1446198

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 30
Study: 6736272

Group type: EXPERIMENTAL
Intervention: Haloperidol (plasma levels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol (red blood cell levels)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol (plasma/red blood cell ratio)
Number of subjects: 0
Study: 30393935

Group type: EXPERIMENTAL
Intervention: ATRA plus chemotherapy
Number of subjects: 83

Group type: COMPARATOR
Intervention: ATRA only
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO)
Number of subjects: 83

Group type: COMPARATOR
Intervention: No arsenic trioxide (no ATO)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Overall treatment (ATRA, cytarabine, anthracyclines)
Number of subjects: 83
Study: 29450452

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus regional hyperthermia
Number of subjects: 341

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy alone
Number of subjects: 341
Study: 24983200

Group type: EXPERIMENTAL
Intervention: UBV (60 s ultra-brief video on CO-CPR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (CTR: sat idle for 60 s)
Number of subjects: 100
Study: 22825691

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2 intravenously over 3 h) plus Carboplatin (AUC 5 intravenously over 30 min)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus Carboplatin
Number of subjects: 13
Study: 20178395

Group type: EXPERIMENTAL
Intervention: Personalized letter from a practicing pharmacist containing treatment recommendations for patients with upcoming primary care visits (intervention group, n = 150)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Usual care without the letters (control group, n = 151)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Personalized letter from a practicing pharmacist (intervention group)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Usual care without the letters (control group)
Number of subjects: 346
Study: 17141481

Group type: EXPERIMENTAL
Intervention: Anti-Helicobacter pylori treatment (clarithromycin, amoxicillin, lansoprazole)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Probiotic combination (Lactobacillus rhamnosus GG, L. rhamnosus LC705, Propionibacterium freudenreichii ssp. shermanii JS, Bifidobacterium breve Bb99)
Number of subjects: 39

Group type: COMPARATOR
Intervention: H. pylori-negative control group
Number of subjects: 39
Study: 15657401

Group type: EXPERIMENTAL
Intervention: Maintenance rituximab therapy (standard 4-week courses administered at 6-month intervals)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Rituximab re-treatment at progression
Number of subjects: 114
Study: 12111340

Group type: EXPERIMENTAL
Intervention: Savoxepine
Number of subjects: 87

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 87
Study: 9647677

Group type: EXPERIMENTAL
Intervention: manual line bisection task
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: line bisection task by fixation
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: tasks with lines with no landmark
Number of subjects: 3
Study: 7794307

Group type: EXPERIMENTAL
Intervention: Fluconazole 3 mg/kg once daily
Number of subjects: 502

Group type: COMPARATOR
Intervention: Nystatin 50,000 U/kg four times daily
Number of subjects: 502

Group type: COMPARATOR
Intervention: Amphotericin B 25 mg/kg four times daily
Number of subjects: 502
Study: 3277911

Group type: EXPERIMENTAL
Intervention: OKY‐046 (400 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: OKY‐046 (600 mg/day for 3 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg) + OKY‐046
Number of subjects: 9
Study: 31650650

Group type: EXPERIMENTAL
Intervention: Urinary balloon catheter
Number of subjects: 324

Group type: COMPARATOR
Intervention: Compression with thorax pressure bandage (Control)
Number of subjects: 324
Study: 30203101

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended-release (TA-ER) 32 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard triamcinolone acetonide crystalline suspension (TAcs) 40 mg
Number of subjects: 33
Study: 28192225

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 73

Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 73
Study: 24373064

Group type: EXPERIMENTAL
Intervention: Interacting with the companion robot, Paro
Number of subjects: 17
Study: 24157260

Group type: EXPERIMENTAL
Intervention: Trained AYUSH providers (narrative prevention counseling)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Untrained providers (standard care)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Trained AYUSH providers
Number of subjects: 554

Group type: COMPARATOR
Intervention: Untrained providers
Number of subjects: 554
Study: 21146184

Group type: EXPERIMENTAL
Intervention: Whole-body hypothermia
Number of subjects: 204

Group type: COMPARATOR
Intervention: Intensive care alone
Number of subjects: 204
Study: 18061001

Group type: EXPERIMENTAL
Intervention: New antiarrhythmic drugs
Number of subjects: 0
Study: 16489888

Group type: EXPERIMENTAL
Intervention: In-line filter placement
Number of subjects: 442

Group type: COMPARATOR
Intervention: No filter placement
Number of subjects: 442
Study: 14604933

Group type: EXPERIMENTAL
Intervention: Handheld computer clinical decision support tool
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Pocket card containing guidelines
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 169
Study: 10783213

Group type: EXPERIMENTAL
Intervention: Defibrillator implantation
Number of subjects: 3559

Group type: EXPERIMENTAL
Intervention: Hospital discharge while taking a beta-blocker
Number of subjects: 3559

Group type: EXPERIMENTAL
Intervention: Hospital discharge while taking an angiotensin-converting enzyme inhibitor
Number of subjects: 3559

Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 3559

Group type: EXPERIMENTAL
Intervention: Multivariate predictors of worse survival
Number of subjects: 3559
Study: 8624314

Group type: EXPERIMENTAL
Intervention: Inactive urinary kallikrein to creatinine ratio (IUK:Cr) measured on an untimed urine sample
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Inactive urinary kallikrein to creatinine ratio (IUK:Cr) in women who developed proteinuric pre‐eclampsia
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Inactive urinary kallikrein to creatinine ratio (IUK:Cr) in women who developed pre‐eclampsia
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Receiver-operator characteristics analysis
Number of subjects: 307
Study: 1304178

Group type: EXPERIMENTAL
Intervention: Pumice prophylaxis with a rubber cup, etched for 30 seconds
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pumice prophylaxis, etched for 60 seconds
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/NaF dentifrice prophylaxis, etched for 30 seconds
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/NaF dentifrice prophylaxis, etched for 60 seconds
Number of subjects: 60
Study: 3886402

Group type: EXPERIMENTAL
Intervention: Cadralazine 15 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlorthalidone 25 mg/day
Number of subjects: 20
Study: 30326380

Group type: EXPERIMENTAL
Intervention: Methadone 0.1 mg kg-1
Number of subjects: 70

Group type: COMPARATOR
Intervention: Morphine 0.1 mg kg-1
Number of subjects: 70
Study: 30267045

Group type: EXPERIMENTAL
Intervention: Foster Care Group (FCG)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Care as Usual Group (CAUG)
Number of subjects: 220
Study: 27542517

Group type: EXPERIMENTAL
Intervention: ANWR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 24828386

Group type: EXPERIMENTAL
Intervention: Urinary LT‐E4 concentrations during a migraine episode
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Urinary PG‐F2a concentrations during a migraine episode
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group urinary LT‐E4 concentrations
Number of subjects: 64
Study: 22483372

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 40
Study: 19685085

Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium breve strain Yakult)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 18940484

Group type: EXPERIMENTAL
Intervention: E‐L pretreatment (epinephrine and lidocaine mixture)
Number of subjects: 29
Study: 16088363

Group type: EXPERIMENTAL
Intervention: High-dose simvastatin (80 mg/daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Simvastatin 20 mg/daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 12017384

Group type: EXPERIMENTAL
Intervention: Isoflurane administration via microporous capillary membrane oxygenator
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane administration via diffusion membrane oxygenator
Number of subjects: 60